Lynn D. Kramer, MD
Lynn D. Kramer, M.D., is the President of the Eisai Neuroscience Product Creation Unit, where he oversees the full product creation cycle, including licensing activities, from discovery through regulatory approval of innovative projects in the neuroscience area. Prior to his employment at Eisai, he had positions in a number of pharma companies, large and small, during his 23 year industry career including PAR Pharmaceutical, Inc., Purdue Pharmaceuticals, Ciba Geigy, Novartis, the R.W. Johnson Pharmaceutical Research Institute, and Carter-Wallace, Incorporated. During his career he has lead teams and groups accounting for 17 NDAs and has been responsible for leading the Neuroscience Therapeutic Area Strategy Team at Ciba and Novartis, which included discovery research, clinical development, and global marketing. He is a Fellow of the American Board of Psychiatry and Neurology (1987). He has had multiple grants and has been CO-Prinicipal Investigator on a large NIH-sponsored Program Project and other projects. He has more than 90 publications (chapters, journal articles, abstracts). He received his M.D. from Hahnemann Medical College, completed his internship in Internal Medicine at the University of California at Irvine and his residency in Neurology at the University of Virginia.